CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2020—Baebies announced that its Finder platform is CE marked as an in vitro diagnostic device and commercially available in Europe and other countries that recognize the CE mark. The platform includes an instrument and a cartridge, which tests for glucose-6-phosphate dehydrogenase from 50 μL of whole blood. Features of the platform include an eight-inch-wide footprint, preloaded consumables with all necessary reagents, and a turnaround time of approximately 15 minutes from sample introduction.
Finder is designed for use in hospital nurseries, laboratories, neonatal intensive care units, and birthing centers. It is undergoing a clinical trial in the U.S. for FDA clearance of the near-patient platform and the test panel that includes testing of G6PD enzyme activity.